Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Number of Pharmacies in Japan Rises to 54,780 as of FY2011 End: MHLW
October 29, 2012
- MHLW Unveils Action Plan for 5-Year Clinical Trial Activation Plan
October 26, 2012
- MHLW to Initially Limit Number of Stores to Offer Epadel OTC
October 26, 2012
- US Paperwork Reduction Act Will Not Affect ICH PBRER Guidelines: MHLW
October 26, 2012
- BBPD to Seek Reductions in Market Prices of Domestic Blood Products: New BBPD Director Kato
October 26, 2012
- Basic Bill for Regenerative Medicine to Be Submitted to Extraordinary Diet by Bipartisan Lawmaker-Initiated Legislation
October 26, 2012
- METI and MEXT Call for Increase in R&D Tax Credit
October 25, 2012
- Generic-Only Requirement for People on Welfare “Would Be Problematic”: Health Minister Mitsui
October 24, 2012
- MOF Asks Committee to Discuss Mandatory Generic Drug Use for People on Welfare
October 24, 2012
- MHLW Project to Study Generic Evaluation Criteria Gets Underway
October 23, 2012
- Health Minister Mitsui Pledges Seamless Support for New Drug Development
October 22, 2012
- Sales Tax Hike Expected to Hasten Separation of Dispensing from Medical Practice by Sapping Yakka-Saeki
October 19, 2012
- FSA to Determine Whether Infertility Treatment Should Be Covered by Private Insurers
October 19, 2012
- PAFSC’s Second Committee to Review Additional Indication for Afinitor on Oct. 31
October 19, 2012
- PAFSC Committee Recommends Approval for Switch OTC Version of Epadel 2 Years after Frist Review
October 18, 2012
- MHLW’s FY2013 Budget Request Seeks More Funding Aimed at Reducing the Drug Lag Based on Results of Policy Evaluation
October 18, 2012
- MHLW to Compile New Generic Share Goal, Roadmap within FY2012
October 17, 2012
- Generic Substitution Could Save 1.53 Trillion Yen in Healthcare Spending: MOF
October 17, 2012
- Former Health Minister Nagatsuma to Take Over as Chairman of Lower House Committee on Health, Labor and Welfare
October 17, 2012
- Mochida’s Epadel Hastily Added to Review List for PAFSC’s Committee on Non-Prescription Drugs
October 16, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…